Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantSC
Surveyor Capital
Activity from announced rounds
All recorded activity
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.2B 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in all activityAdcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedSoley Therapeutics
Uses cells as sensors to uncover first-in-class medicines
$200MSeries C
Role not disclosedKailera Therapeutics
Kailera Therapeutics develops oral and injectable medicines for obesity using several GLP-1-based mechanisms.
$600MSeries B
Participant